- Ivy Leaf Extract
-
- $10.00 / 1kg
-
2025-04-24
- CAS:14216-03-6
- Min. Order: 1kg
- Purity: Hederacoside C 3%
- Supply Ability: 10000
- Hederacoside C
-
- $42.00 / 20mg
-
2024-11-19
- CAS:14216-03-6
- Min. Order:
- Purity: 99.58%
- Supply Ability: 10g
- Hederacoside C
-
- $0.00 / 25kg
-
2024-04-12
- CAS:14216-03-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
|
| | Hederacoside C Basic information |
| | Hederacoside C Chemical Properties |
| Melting point | 222 °C (dec.)(lit.) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly, Sonicated), Pyridine (Sparingly) | | pka | 12.50±0.70(Predicted) | | form | Solid | | color | White to Pale Beige | | BRN | 4229541 | | Stability: | Hygroscopic | | InChIKey | RYHDIBJJJRNDSX-MCGLQMIESA-N | | LogP | 4.520 (est) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 22-24/25 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | F | 10-23 | | HS Code | 29389090 |
| | Hederacoside C Usage And Synthesis |
| Chemical Properties | White powder | | Uses | solubilizer, bio-availability enhancer in oral suspensions, capsules | | Uses | Hederacoside C is a Hedera helix leaf which has been used in botanical drug formulations to treat acute respiratory infection and bronchitis. Anti-myocardial. | | Definition | ChEBI: A triterpenoid saponin with hederagenin as the aglycone part. It has been isolated from the stem bark of Kalopanax pictus. | | in vivo | Hederacoside C (0.625, 1.25, 2.5 mg/kg, intraperitoneally injected for 7 consecutive days) can alleviate TNBS-induced enteritis[1].
Hederacoside C (5, 10, 50 mg/kg, intraperitoneally injected for 3 consecutive times for 8 h) can attenuate the breast lesions caused by Staphylococcus aureus[2].
| Animal Model: | TNBS-induced colitis in rat[1] | | Dosage: | 0.625, 1.25, 2.5 mg/kg | | Administration: | i.p. for 7 days | | Result: | Decreased the levels of inflammatory cytokines, including TNF-α, IL-6, IL-1β, CXCL-1, CXCL-2, and CXCL-5.
Reduced cell apoptosis in TNBS-induced colitis.
Reduced Bax/Bcl-2 ratio, cleaved caspase 3, and p53 protein levels in a dose-dependent manner.
|
|
| | Hederacoside C Preparation Products And Raw materials |
|